Latest Breaking News On - Gastaut syndrome - Page 1 : comparemela.com

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesLuis sanayJeffreym daynoEpygenix company presentationEuropean medicines agencyEpygenix therapeutics incExchange commissionEuropean unionShare repurchase programHarmony biosciences holdings incParagon biosciencesDrug administrationIts growth strategyAdvances pitolisant franchiseExtend revenue potential beyond

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its

WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year

United kingdomUnited statesLuis sanayJeffreym daynoEpygenix therapeutics incExchange commissionEpygenix company presentationShare repurchase programEuropean unionEuropean medicines agencyHarmony biosciences holdings incDrug administrationParagon biosciencesNet revenueFirst quarterNew drug application

Lennox-Gastaut Syndrome Global Clinical Trials Review 2024:

Dublin, April 23, 2024 (GLOBE NEWSWIRE) The

United statesLundbeck foundationHumanwell healthcare group co ltdTakeda pharmaceutical co ltdThermo fisher scientific incSawai group holdings co ltdSumitomo corpEisai co ltdJazz pharmaceuticals plcGastaut syndromeClinical trials reviewLennox gastaut syndrome clinicalTrial statusTrial phaseSponsor typeGlobal clinical trials market

Dravet syndrome treatment market size to increase by USD 575 14 million between 2022-2027, Technavio

/PRNewswire/ The Dravet Syndrome Treatment Market by Product, Distribution Channel, and Geography - Forecast and Analysis 2023-2027 report has been.

United kingdomUnited statesStiripentol diacomitJesse maidaDrug administrationEuropean medicines agencyDravet foundationTechnavio researchDravet syndrome treatment marketDistribution channelRegulatory designations propel market growthNeuroene therapeuticMarket trends pointEnhanced treatment efficacyPersist amid promising growthPlayers forge ahead

Nippon Shinyaku : UCB Japan Obtained Additional Application of Fintepla® (fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome in Japan -March 26, 2024 at 03:06 am EDT

NEWS RELEASE March 26, 2024 UCB Japan Obtained Additional Application of Fintepla® for the Treatment of Seizures.

Bruxelles capitaleToru nakaiKanako kikuchiZogenix incJapan coCorporate communications deptMinistry of healthNippon shinyaku co ltdObtained additional applicationSeizures associatedGastaut syndromeNippon shinyakuOral solutionCommunications dept